Clinical Trials Directory

Trials / Unknown

UnknownNCT00188084

Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia

Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (planned)
Sponsor
University Hospital, Angers · Other Government
Sex
All
Age
15 Years – 59 Years
Healthy volunteers
Not accepted

Summary

Adult acute lymphoblastic leukemia treatment approaches relie on risk stratification, including cytogenetics. We want to study at diagnosis several blast cells parameters on frozen samples of GRAALL protocols enrolled patients: 1. A CD45-DNA double staining analysed by flow cytometry will allow mesurement for each blastic clone of DNA ploidy, percentage of cells in S-phase, CD45 fluorescence index. 2. The proteine P16 metabolic way, involved in cell cycle regulation, will be studied by Western Blot analysis. The comparison between these parameters, and main haematological data, will be followed by a prognostic analysis, based on blast corticosensibility in vivo, chimiosensibility, complete remission, and survival. Combination of the studied parameters will allow to appreciate a clonal diversity. This will help to predict, at diagnosis, high probability of resistance to treatment.

Conditions

Interventions

TypeNameDescription
PROCEDUREDNA Index
PROCEDURES-Phase%
PROCEDURECD45 expression
PROCEDUREP16 metabolic way

Timeline

Start date
2003-11-01
Completion
2005-09-01
First posted
2005-09-16
Last updated
2005-10-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00188084. Inclusion in this directory is not an endorsement.